-
Mashup Score: 11A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single-cell analysis - 4 month(s) ago
In situ vaccination (ISV) triggers an immune response to tumor-associated antigens at 1 tumor site, which can then tackle the disease throughout the b…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Energy overpowers sweet tooth in FL - 4 month(s) ago
Journals & BooksSearchRegisterSign inView PDFSearch ScienceDirectBloodVolume 142, Issue 26, 28 December 2023, Pages 2226-2229Author links open overlay panelhttps://doi.org/10.1182/blood.2023022268Get rights and contentCited by (0)View Abstract© 2023 by The American Society of Hematology
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
Especially appreciative of the thoughtful commentary by Hendrik Veelken highlighting potential biological and clinical implications: https://t.co/knFfhBn1oy
-
-
Mashup Score: 2Follicular lymphoma evolves with a surmountable dependency on acquired glycosylation motifs in the B-cell receptor - 4 month(s) ago
An early event in the genesis of follicular lymphoma (FL) is the acquisition of new glycosylation motifs in the B-cell receptor (BCR) due to gene rear…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
In @BloodJournal, we confirm that most FL tumor cells acquire glycosylation sites in their BCR, but show that in some patients or subclones, tumor cells thrive without acquired sites, turning to metabolic rewiring to compensate for less BCR signaling. https://t.co/spUT50ZcdI
-
-
Mashup Score: 3The 2022 generation - 1 year(s) ago
Twelve early career investigators share experiences from the process of starting their laboratories throughout the past year, and reflect on the challenges faced and the opportunities seized.
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Thanks to @NatureCancer for highlighting the perspectives of our generation, and for including views from junior scientists around the world. Excited and hopeful for the future! https://t.co/44EYa2q9OK
-
-
Mashup Score: 2CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity - 2 year(s) ago
To obtain a deeper understanding of poor responses to COVID-19 vaccination in lymphoma patients, we assessed blocking antibodies, total anti-spike IgG, and spike-specific memory B cells in the peripheral blood of 126 patients with lymphoma and 20 age-matched healthy controls 1 and 4 months after COVID-19 vaccination. Fifty-five percent of patients developed blocking antibodies post-vaccination,…
Source: Blood Cancer DiscoveryCategories: Hem/Oncs, Latest HeadlinesTweet-
We are recommending vaccinating/boosting before treatment in all who can wait a little before starting anti-CD20-based treatment and haven't yet been vaccinated/boosted. Full manuscript @BCD_AACR: https://t.co/zqi6nh6lfr /end
-
-
Mashup Score: 4Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma - 3 year(s) ago
Tumor heterogeneity complicates biomarker development and fosters drug resistance in solid malignancies. In lymphoma, our knowledge of site-to-site he…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Lymphoma is a systemic disease, but is lymphoma at one site the same as at another? Frequently not in FL! Check out our study in Blood plus excellent commentary by Tobin & Gandhi for additional context. @blood #lymsm #singlecell https://t.co/8phIgCG6sG
-
-
Mashup Score: 2
PURPOSE Therapeutic advances for diffuse large B-cell lymphoma (DLBCL) have led to an increasing number of survivors. Both DLBCL and its treatments perturb the immune system, yet little is known about immune health during extended survivorship. METHODS In this retrospective cohort study, we compared 21,690 survivors of DLBCL from the California Cancer Registry (CCR) to survivors of breast,…
Source: Journal of Clinical OncologyCategories: Hem/OncsTweet-
Proud to present our study finding impaired immune health among >21,000 DLBCL survivors. Increased risk for new diagnoses of infections, immune deficiencies, and autoimmune conditions during extended survivorship. #lymsm #dlbcl @StanfordMed @ucdavis https://t.co/gzuOBqbxXi
-
In @BloodAdvances, our trial combining ibrutinib with in situ vaccination in lymphoma shows that combinatorial stimulation and inhibition of different aspects of the immune system can synergize to generate meaningful clinical responses. https://t.co/D1NtIbYlXS